Cigna Group rated Buy with strong growth and dividend prospects through 2031 at a 29% discount to fair value.

Cigna Group is rated as a Buy due to expected double-digit adjusted income per share growth starting in 2027, driven by its pharmacy segment, biosimilar adoption, behavioral health expansion, and aggressive share buybacks. The stock trades at an 8.5x forward P/E, representing a 29% discount to its fair value, supporting a projected 17% annual total return through 2031. The company has a robust dividend safety profile with a low payout ratio and an A+ Quant grade, indicating potential for continued and accelerating dividend growth. These factors make Cigna an attractive investment opportunity for dividend growth investors looking for long-term returns.